The upgrade from Neutral to Overweight by Piper Sandler indicates a positive outlook for Axsome Therapeutics. The raised price target from $70 to $90 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock's price in the short term.